Home » Liverpool CMO Opens GMP Manufacturing Facility
Liverpool CMO Opens GMP Manufacturing Facility
PharmaManufacturing.com
05/21/2007
Eden Biodesign Ltd., a fast-growing biopharmaceutical development and manufacturing services company, announced May 21 that it has been awarded a licence by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture Investigational Medicinal Products (IMPs) at its new state-of-the art facility in Liverpool, UK.
The UK National Biomanufacturing Centre operated by Eden Biodesign came on-line for process and analytical development in May 2006. The MHRA inspection took place earlier this year to certify Eden’s processes and facilities as having reached the international Good Manufacturing Practices (cGMP) standard. The new license will provide legal authority for Eden to manufacture biopharmaceutical drug substances under contract for clients for use in EU clinical trial sites.
Dr. Crawford Brown, CEO of Eden Biodesign, commented: “Eden is now fully on track and able to deliver a full range of services for the production of mammalian, microbial and virus-based experimental medicines for a worldwide client base.”
He added, “We are particularly delighted as we designed the UK Biomanufacturing Centre that we operate and the MHRA license is recognition of our expertise in process development, cGMP manufacturing for clinical studies of new medicines and analytical development”.
Following the successful inspection, Eden recently announced that it will provide ImmBio, based in Cambridge, UK, with a range of development and manufacturing services to rapidly advance their leading influenza vaccine forward towards a Clinical Trial Application.
Eden has also started to supply cGMP clinical manufacturing services to Onyvax, a private UK biotech company, for its ovarian cancer vaccine and extended a project with Silence Therapeutics plc (formerly SR Pharma plc), delivering the listed UK biotech with a whole cell microbial immunotherapeutic for the treatment of asthma and as a therapeutic in cancer and tuberculosis. For further information, visit www.edenbiodesign.com.
More News:
- 03/05/2010 Glaxo Could Face $6bn Avandia Liability, Says UBSFrom Guardian.co.uk
- 03/05/2010 Planned Job Cuts Drop 41%; 16% for Pharma Industry
- 03/04/2010 AstraZeneca Shuffles, Eliminates Del. R&D Jobs
- 03/03/2010 Germany's Merck to Acquire MilliporeFrom NYTimes.com
- 03/03/2010 FDA Releases Final Guidance on Characterization of Cell Substrates and Bio Materials for Viral Vaccines
- 02/25/2010 Tobacco-based Vaccine Initiative LaunchedFrom Texas A&M University
- 02/25/2010 Lilly Cited for Quality Issues in P.R. Humalog Facility
- 02/23/2010 DSM Receives Profiles in Sustainability Award for Pharma Manufacturing Technology
- 02/22/2010 Thermo Fisher Said to Offer $6 Billion for MilliporeFrom Bloomberg.com
- 02/22/2010 NanoGuardian and Capsugel Announce Global Anti-Counterfeiting Collaboration
- All news »
Get Connected Now!
- Featured White Papers

Print page